COVID-19TOCCIPNCT04433325
COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units
An observational study of COVID-19 and Intensive Care Unit Syndrome, run by Rennes University Hospital at 2 sites in France.
Trial summary
Since early 2020, France knows a sanitary crisis with a massive influx of COVID-19 patients admitted in Intensive Care Units (ICU). It led to a saturation of the French health system, especially in some geographic areas such as East of France or Paris region. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19, Intensive Care Unit Syndrome
- How many people
- 37 participants
- Where
- 2 sitesFrance
- Study dates
- 30 Jul 2020to 6 Oct 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: COVID-19 positive patients admitted in Intensive Care Unit between 15/03/2020 and 15/04/2020
Who may be able to join
- Age > 18 years
- COVID-19 positive patients admitted in Intensive Care Unit between 15/03/2020 and 15/04/2020
- Patients (or legal representative) with no opposition to inclusion in medical research protocol
- Regarding case group : Patients transferred from Paris's ICU
- Regarding case control group : Patients admitted in ICU with no transfer from Paris
Who cannot join
- > 18 years under legal protection and patients with liberty restriction
Trial locations and contacts
2 sites in 1 country.
About this study
Since early 2020, France knows a sanitary crisis with a massive influx of COVID-19 patients admitted in Intensive Care Units (ICU). It led to a saturation of the French health system, especially in some geographic areas such as East of France or Paris region. Therefore, authorities decided to transfer some critically ill patients from these crowded ICUs to less busy regional ICUs. it was done for the first time by medical train transportation. Knowing that the investigators lack experience regarding this type of medical evacuation, regarding the high number of transferred patients, with such a logistic effort, the investigators decided to study this phase of the COVID-19 sanitary crisis in order to draw a feedback. So far, there are no data in the literature regarding this topic.
- Conditions
- COVID-19, Intensive Care Unit Syndrome
- Keywords
- Medical transport by train
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients transferred | Patients transferred from Paris's Intensive Care Units | |
| Patients not transferred | Patients admitted in Intensive Care Units with no transfer from Paris |
What is being measured
The primary outcome is the main question the study is designed to answer.
number of death
to evaluate mortality
Measured: at Intensive Care Units discharge, an average of 1 months
Secondary outcomes (7)
number of infections
to evaluate morbidity
Measured: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days of mechanical ventilation
Measured: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days of sedation
Measured: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days of use of neuromuscular blocking agents
Measured: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days of vasopressor use
Measured: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days in Intensive Care Units
Measured: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days in hospital
Measured: from date of admission until hospital discharge, assessed up to 1 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jun 2020
- Study start30 Jul 2020
- Primary completion6 Aug 2020
- Study completion6 Oct 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- More trials run by Rennes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 37 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rennes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Benoît Painvin, Principal investigator, Rennes University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04433325
- Sponsor's protocol ID
- 35RC20_3091_TOCCIP
- Acronym
- TOCCIP
- Status last verified
- Jun 2026
- First submitted
- 12 Jun 2020
- Last updated
- 12 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units
- ClinicalTrials.gov ID
- NCT04433325
- Acronym / sponsor ID
- TOCCIP / 35RC20_3091_TOCCIP
- Conditions
- COVID-19, Intensive Care Unit Syndrome
- Keywords
- Medical transport by train
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 37 participants (actual)
- Lead sponsor
- Rennes University HospitalUniversity, hospital or other
- Study start
- 30 Jul 2020 (actual)
- Primary completion
- 6 Aug 2020 (actual)
- Study completion
- 6 Oct 2020 (actual)
- First posted
- 16 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Since early 2020, France knows a sanitary crisis with a massive influx of COVID-19 patients admitted in Intensive Care Units (ICU). It led to a saturation of the French health system, especially in some geographic areas such as East of France or Paris region. Therefore, authorities decided to transfer some critically ill patients from these crowded ICUs to less busy regional ICUs. it was done for the first time by medical train transportation. Knowing that the investigators lack experience regarding this type of medical evacuation, regarding the high number of transferred patients, with such a logistic effort, the investigators decided to study this phase of the COVID-19 sanitary crisis in order to draw a feedback. So far, there are no data in the literature regarding this topic.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients transferred | – | –Patients transferred from Paris's Intensive Care Units |
| Patients not transferred | – | –Patients admitted in Intensive Care Units with no transfer from Paris |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- COVID-19 positive patients admitted in Intensive Care Unit between 15/03/2020 and 15/04/2020
Key inclusion criteria (5 listed)
- Age > 18 years
- COVID-19 positive patients admitted in Intensive Care Unit between 15/03/2020 and 15/04/2020
- Patients (or legal representative) with no opposition to inclusion in medical research protocol
- Regarding case group : Patients transferred from Paris's ICU
- Regarding case control group : Patients admitted in ICU with no transfer from Paris
Key exclusion criteria (1 listed)
- > 18 years under legal protection and patients with liberty restriction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
number of death
Time frame: at Intensive Care Units discharge, an average of 1 months
to evaluate mortality
7 secondary outcomes
number of infections
Time frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days of mechanical ventilation
Time frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days of sedation
Time frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days of use of neuromuscular blocking agents
Time frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days of vasopressor use
Time frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days in Intensive Care Units
Time frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
number of days in hospital
Time frame: from date of admission until hospital discharge, assessed up to 1 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benoît Painvin principal investigator
Rennes University Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Intensive Care Unit Syndrome, run by Rennes University Hospital at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
number of death (time frame: at Intensive Care Units discharge, an average of 1 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.